Black checkmark with a sparkle and a curved line underneath on a white background.
Company

UNITED GUARDIAN INC

Ticker
UG
Sector
Industry
Report date
November 12, 2026
Valye AI Score

100

Very high visibility
Recent developments
Recent developments summary

Recent news highlights significant sales growth and profit advances in 2026, driven by strong cosmetic ingredient sales and increased demand for pharmaceutical products. The company continues dividend payments and expands distribution agreements.

Recent developments:
  • United-Guardian reported a 54% increase in third quarter 2026 net sales, with profit advances in Q3 driven by strong cosmetic ingredient sales [N1][N2][N3].
  • The company declared a cash dividend in July 2026, continuing a 30-year consecutive dividend payment history [N4].
  • First quarter 2026 earnings rose year-over-year due to strong demand for Renacidin [N5][N6].
  • In 2025, earnings fell year-over-year amid weak sales trends, particularly in cosmetics, with Q2 and Q3 2025 earnings declining due to weak cosmetic sales despite some pharmaceutical gains [N7][N8].
Overview

United-Guardian, Inc. is a Delaware corporation focused on manufacturing, marketing, and developing specialty cosmetic, personal care, sexual wellness ingredients, and healthcare products including pharmaceuticals and medical lubricants. The company emphasizes product innovation and natural, environmentally friendly raw materials. Its product portfolio includes the Lubrajel line of hydrogels for cosmetics and medical lubricants, FDA-approved pharmaceuticals like Renacidin, and a new Natrajel line for sexual wellness. Products are manufactured primarily at its Hauppauge, New York facility, except for Renacidin, which is contract manufactured. United-Guardian sells its products globally through a network of distributors and wholesalers, including major partners such as Ashland Specialty Ingredients and Brenntag Specialties. The company conducts ongoing research and development to expand product applications and markets [S1].

Executive summary

Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. United-Guardian, Inc. manufactures and markets specialty cosmetic, personal care, sexual wellness ingredients, and healthcare products including pharmaceuticals and medical lubricants. The company operates a single business segment with four product categories and sells globally through distributors and wholesalers. Recent financial results show improved sales and profitability in 2026 compared to 2025, with strong growth in cosmetic ingredient sales and continued demand for pharmaceutical products such as Renacidin. The company maintains strong liquidity with a current ratio of 6.5 as of September 30, 2026 [S1][S2][N1][N2][N3].

Scenarios for UG

Bull case model:

United-Guardian's recent sales growth, particularly a 54% increase in Q3 2026 net sales and profit advances driven by strong cosmetic ingredient sales, indicates operational momentum. The company's expansion of distribution agreements, including the new Natrajel line with Brenntag Specialties, and increased formulary coverage for Renacidin through pharmacy benefit managers support commercial growth. Strong liquidity and consistent dividend payments reflect financial stability [N1][N2][N3][N4][N5].

Bear case model:

The company experienced earnings declines in 2025 due to weak sales trends, especially in cosmetics, with Q2 and Q3 2025 earnings falling year-over-year. Pricing pressure from low-cost competitors in the hydrogel market poses ongoing risks. Dependence on a limited number of distributors and wholesalers for product sales could impact revenue if relationships change. The niche nature of some products may limit market size and growth potential [N7][N8][S1].

Moat:

United-Guardian's moat is supported by its specialized product innovation in hydrogel formulations for cosmetics, medical lubricants, and sexual wellness applications, including natural and preservative-free certified products. Its long-standing relationships with global distributors and wholesalers, proprietary formulations protected as trade secrets, and FDA-approved pharmaceutical products contribute to competitive differentiation. The company's ability to adapt to market demands for green and sustainable products and its established manufacturing facility provide operational stability. However, pricing pressure from low-cost competitors remains a challenge [S1].

Risks overview
Risks summary
Key risks include competitive pricing pressure, dependence on a few distributors, demand variability in core product lines, and regulatory/manufacturing challenges.
Risks details:

• Market Competition and Pricing Pressure: United-Guardian faces significant pricing pressure from low-cost competitors in the specialty hydrogel market, which could impact margins and sales volumes [S1].
• Distributor and Customer Concentration: The company relies on a limited number of distributors and wholesalers for global sales, including Ashland Specialty Ingredients and Brenntag Specialties. Changes in these relationships could disrupt sales channels [S1].
• Product Demand Variability: Fluctuations in demand for cosmetic ingredients and pharmaceuticals, as seen in 2025 earnings declines, pose risks to revenue stability [N7][N8].
• Regulatory and Manufacturing Risks: Pharmaceutical products require FDA approval and compliance; reliance on a contract manufacturer for Renacidin introduces operational risk [S1].

FINAL FORECAST FOR UG

Final take one line
United-Guardian exhibits very high visibility with detailed disclosures and recent news showing sales growth and operational stability amid competitive and market challenges.
Final take 12 to 24 month view

Business trends: Growth in cosmetic ingredient sales and pharmaceutical demand, expansion of distribution agreements, and sustained dividend payments.
Execution milestones: Increased formulary coverage for Renacidin, new distribution agreements for sexual wellness products, and consistent quarterly profitability.
Key risks: Competitive pricing pressure, distributor concentration, demand variability in cosmetics and pharmaceuticals, and regulatory/manufacturing dependencies.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

100
LLM visibility overview
LLM Visibility known facts
  • United-Guardian, Inc. is a Delaware corporation operating primarily through its Guardian Laboratories division, manufacturing, marketing, and developing specialty cosmetic, personal care, sexual wellness ingredients, and healthcare products including pharmaceuticals and medical lubricants [S1].
  • The company conducts research and development focused on new and unique specialty cosmetic and sexual wellness ingredients, emphasizing natural and environmentally friendly raw materials [S1].
  • All products except Renacidin are produced at the Hauppauge, New York facility; Renacidin is manufactured by an outside contract manufacturer [S1].
  • United-Guardian operates as a single business segment with four product categories: cosmetic ingredients, pharmaceuticals, medical lubricants, and sexual wellness ingredients [S1].
  • Cosmetic ingredients include the Lubrajel line of multifunctional hydrogel formulations used in skin care and makeup products, with a focus on natural and preservative-free products certified by COSMOS [S1].
  • Medical lubricants are sold directly to manufacturers and marketers of finished medical products and contract manufacturers, used in catheters, surgical instruments, oral care, and condoms [S1].
  • Pharmaceutical products include FDA-approved prescription drugs such as Renacidin and Clorpactin, sold primarily through national full-line drug wholesalers to pharmacies, hospitals, and government agencies [S1].
  • Sexual wellness ingredients include hydrogel formulations for sensory enhancement and lubrication, with a new Natrajel line distributed in North America and France via Brenntag Specialties [S1].
  • The company sells cosmetic ingredients globally through five distributors, with Ashland Specialty Ingredients (ASI) as the largest distributor covering multiple regions; other distributors include Azelis Group NV, Sederma SAS, Safic-Alcan S.p.A., and Azelis Cosmetics GmbH [S1].
  • United-Guardian ships products Ex Works from its Hauppauge facility; cosmetic ingredients are not sold on consignment and are generally non-returnable unless defective [S1].
  • The company has been developing marketing strategies to expand Renacidin sales, including gaining approval from two major pharmacy benefit managers for formulary inclusion as of February 2026 [S1].
  • Recent quarterly financial data for Q3 2026 shows net sales of $3.49 million, income from operations of approximately $1.11 million, and net income of $930,912 with basic earnings per share of $0.20 [S2].
  • As of September 30, 2026, United-Guardian held $1.41 million in cash and cash equivalents and $7.34 million in marketable securities, with total current assets of $12.58 million and current liabilities of approximately $1.94 million, resulting in a current ratio of 6.5 and a cash ratio of 4.71 [S2].
  • The company reported a 54% increase in third quarter 2026 net sales and profit advances in Q3 2026, driven by strong cosmetic ingredient sales [N1][N2][N3].
  • United-Guardian declared a cash dividend in July 2026, continuing a 30-year consecutive dividend payment history [N4].
  • First quarter 2026 earnings rose year-over-year due to strong demand for Renacidin [N5][N6].
  • In contrast, 2025 earnings fell year-over-year amid weak sales trends, particularly in cosmetics, with Q2 and Q3 2025 earnings declining due to weak cosmetic sales despite some pharmaceutical gains [N7][N8].
Sources
Sources - Context summary

Generated 2026-11-12

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-03-27 | 10-K
  • S2 | 2026-11-12 | 10-Q
Sources - News headlines
  • N1 | 2026-11-09 | www.nasdaq.com | United-Guardian, Inc. Reports 54% Increase in Third Quarter 2026 Net Sales | https://www.nasdaq.com/articles/united-guardian-inc-reports-54-increase-third-quarter-2026-net-sales
  • N2 | 2026-11-09 | www.nasdaq.com | United-Guardian Inc Profit Advances In Q3 | https://www.nasdaq.com/articles/united-guardian-inc-profit-advances-q3
  • N3 | 2026-08-14 | www.nasdaq.com | UG Q2 Earnings Rise Y/Y on Strong Cosmetic Ingredient Sales | https://www.nasdaq.com/articles/ug-q2-earnings-rise-y-y-strong-cosmetic-ingredient-sales
  • N4 | 2026-07-24 | www.nasdaq.com | Cash Dividend On The Way From United-Guardian (UG) | https://www.nasdaq.com/articles/cash-dividend-way-united-guardian-ug
  • N5 | 2026-05-18 | www.nasdaq.com | United-Guardian Q1 Earnings Rise Y/Y on Strong Renacidin Demand | https://www.nasdaq.com/articles/united-guardian-q1-earnings-rise-y-y-strong-renacidin-demand
  • N6 | 2026-05-08 | www.nasdaq.com | United-Guardian Inc Q1 Profit Advances | https://www.nasdaq.com/articles/united-guardian-inc-q1-profit-advances
  • N7 | 2026-03-31 | www.nasdaq.com | United-Guardian 2025 Earnings Fall Y/Y Amid Weak Sales Trends | https://www.nasdaq.com/articles/united-guardian-2025-earnings-fall-y-y-amid-weak-sales-trends
  • N8 | 2025-08-14 | www.nasdaq.com | UG Q2 Earnings Fall Y/Y on Weak Cosmetic Sales, Pharma Gains | https://www.nasdaq.com/articles/ug-q2-earnings-fall-y-y-weak-cosmetic-sales-pharma-gains
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine